検索
Xencor Inc
XNCRウォッチリストに追加
20.210USD
-1.280-5.96%
終値 07-31 16:00（ET）15分遅れの株価
1.50B時価総額
損失額直近12ヶ月PER
詳細情報 Xencor Inc 企業名
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Incの企業情報
企業コードXNCR
会社名Xencor Inc
上場日Dec 03, 2013
最高経営責任者「CEO」Dahiyat (Bassil I)
従業員数250
証券種類Ordinary Share
決算期末Dec 03
本社所在地465 N. Halstead St.
都市PASADENA
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号91107
電話番号16263055900
ウェブサイトhttps://xencor.com/
企業コードXNCR
上場日Dec 03, 2013
最高経営責任者「CEO」Dahiyat (Bassil I)
Xencor Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
よくある質問
Xencor Incの上位5名の株主は誰ですか？
Xencor Incの上位5名の株主は以下のとおりです。Dr. John R. Desjarlais, Ph.D.
Xencor Incの最大の収益源は何ですか？
2026Q4において、Royalties部門がXencor Incにとって最大の収益を生み出しており、その金額は80.28Mで、全収益の63.93%を占めています。